Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
E. Ferranini, S.M. Haffner, B.D. Mitchell, M.P. Stern.
Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome.
Diabetología, 34 (1991), pp. 416-422
[2.]
P. Kekalaine, H. Sarlund, K. Pyorala, M. Laakso.
Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family historiy of diabetes.
Daibetes Care, 22 (1999), pp. 86-92
[3.]
J.V. Neel.
Diabetes Mellitus: a “thrifty” genotype rendered detrimental by “progres”?.
Am J Hum Genet, 14 (1962), pp. 353-362
[4.]
A general cardiovascular risk profile: the Framingham Heart Study.
Am J Cardiol, 38 (1976), pp. 46-51
[5.]
J.H. Fuller, M.J. Shipley, G. Rose, R.J. Jarrett, H. Keen.
Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study.
Br Med J, 287 (1983), pp. 867-870
[6.]
R.J. Jarrett, P. McCartney, H. Keen.
The Bedford Survey: ten year mortality rates in newly diagnosed diabetes, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics.
Diabetología, 22 (1982), pp. 79-84
[7.]
S.B. Heymsfield, K.R. Segal, J. Hauptman, C.P. Lucas, M.N. Boldrin, A. Rissanen, et al.
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obeses adults.
Arch Intern Med, 160 (2000), pp. 1321-1326
[8.]
D.G. Maggs, T.A. Buchanan, C.F. Burant, G. Cline, B. Gumbiner, W.A. Hsueh, et al.
Metabolic effect of troglitazone monotherapy in the type w diabetes mellitus.
Ann Intern med, 128 (1998), pp. 176-185
[9.]
J.D. McGarry.
What if Minkowski had been ageusic? An alternative angle on Diabetes.
Science, 258 (1992), pp. 766-770
[10.]
L. Landsberg, J.B. Young.
The role of the sympathoadrenal system in modulating energy expenditure.
Clin Endocrinol Metab, 13 (1984), pp. 475-499
[11.]
The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood preassure.
Arch Intern Med, 157 (1997), pp. 2413-2446
[12.]
H.O. Lithell.
Effect of antihypertensive drugs on insulin, glucose and lipid metabolism.
Diabetes Care, 14 (1991), pp. 203-209
[13.]
A. Haenni, H. Lithell.
Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
J Hypertens, 17 (1999), pp. S29-S35
[14.]
F. Yakubu-Madus, W.T. Johnson, K.M. Zimmerman, J. Dananberg, M.I. Steinberg.
Metabolic and hemodynamic effect of Moxonidine in the Zuckeer diabetic fatty rat model of type 2 diabetes.
Diabetes, 48 (1999), pp. 1093-1100
[15.]
L. Tomás Abadal.
Efectos de moxonidina en el tratamiento del síndrome metabólico.
Drugs of Today, 35 (1999), pp. 25-32
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición
